The Journal of Urology
Volume 179, Issue 2 , Pages 552-555 , February 2008

Followup of Patients With Interstitial Cystitis Responsive to Treatment With Intravesical Bacillus Calmette-Guerin or Placebo

  • Kathleen Joy Propert

      Affiliations

    • University of Pennsylvania, Philadelphia, Pennsylvania
    • Corresponding Author InformationCorrespondence: Department of Biostatistics and Epidemiology, University of Pennsylvania School of Medicine, Blockley Hall, 6th Floor, 423 Guardian Dr., Philadelphia, Pennsylvania 19104-6021 (telephone: 215-573-7393; FAX: 215-573-4865).
    • ,
  • Robert Mayer

      Affiliations

    • University of Rochester, Rochester, New York
    • ,
  • J. Curtis Nickel

      Affiliations

    • Queens University, Kingston, Ontario, Canada
    • ,
  • Christopher K. Payne

      Affiliations

    • Stanford University, Stanford, California
    • ,
  • Kenneth M. Peters

      Affiliations

    • William Beaumont Hospital, Royal Oak, Detroit, Michigan
    • ,
  • Valerie Teal

      Affiliations

    • University of Pennsylvania, Philadelphia, Pennsylvania
    • ,
  • David Burks

      Affiliations

    • Henry Ford Hospital, Detroit, Michigan
    • ,
  • John W. Kusek

      Affiliations

    • National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland
    • ,
  • Leroy M. Nyberg

      Affiliations

    • National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland
    • ,
  • Harris E. Foster

      Affiliations

    • Yale University, New Haven, Connecticut
    • ,
  • Interstitial Cystitis Clinical Trials Group

Received 23 January 2007

  • Image Result

    Patient accounting through all study phases. Clinical site determination of response status at end of randomized clinical trial at week 34 was used to evaluate whether patient was responder eligible f

    Patient accounting through all study phases. Clinical site determination of response status at end of randomized clinical trial at week 34 was used to evaluate whether patient was responder eligible for long-term followup or nonresponder eligible for open label BCG. Primary end point of randomized clinical trial was based on central review of responder status.

 Study received institutional review board approval at each site.

 Supported by Cooperative Agreements U01 DK54108, U01 DK54125, U01 DK54127, U01 DK54133, U01 DK54138 and U01 DK54158 from the National Institute for Diabetes and Digestive and Kidney Diseases, and University of Maryland General Clinical Research Center Grant M01 RR 16500, General Clinical Research Centers Program, National Center for Research Resources, National Institutes of Health.

 For another article on a related topic see page 764.

PII: S0022-5347(07)02535-9

doi: 10.1016/j.juro.2007.09.035

The Journal of Urology
Volume 179, Issue 2 , Pages 552-555 , February 2008

Article Tools

* Image Usage & Resolution